The C1GALT1 Knockout SK-HEP-1 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human hepatic adenocarcinoma cell line SK-HEP-1, engineered to disrupt the C1GALT1 gene. This polyclonal knockout product provides a heterogeneous pool of cells carrying targeted gene disruptions, offering a robust model to study the functional consequences of C1GALT1 loss without clonal selection. The product is designed for researchers investigating the roles of O-glycosylation in cancer biology, immune recognition, and cell signaling, and it is suitable for a wide range of biochemical and cell-based assays.
The parental SK-HEP-1 cell line was originally isolated from the ascites of a patient with liver adenocarcinoma and exhibits endothelial-like characteristics, including expression of endothelial markers and the ability to form capillary-like structures. These properties make SK-HEP-1 a unique model for studying hepatic endothelial biology, tumor angiogenesis, and the interplay between epithelial and endothelial phenotypes in malignancy. The hepatic adenocarcinoma origin further positions this cell line as a relevant system for liver cancer research, particularly in the context of glycosylation-dependent processes that influence tumor progression and metastasis.
C1GALT1 encodes core 1 ??1,3-galactosyltransferase (C1GalT1), a key glycosyltransferase that synthesizes the core 1 O-glycan (T antigen) by transferring galactose to the Tn antigen. The enzymatic activity of C1GALT1 is strictly dependent on its molecular chaperone COSMC (C1GALT1C1), which is essential for proper folding and function. In the absence of functional C1GALT1, O-glycan biosynthesis is truncated, leading to the accumulation of Tn antigen on glycoproteins such as MUC1, MUC2, podoplanin, CD43, CD44, and PSGL-1. This alteration disrupts downstream pathways including Notch signaling, cell adhesion, and glycosphingolipid biosynthesis, ultimately affecting cellular interactions, migration, and immune responses. Representative molecular factors within this network include C1GALT1, COSMC, Tn antigen, T antigen, ST6GalNAc-I, and mucins, many of which are transcriptionally regulated or form complexes that modulate glycoprotein trafficking and signaling.
In the SK-HEP-1 context, C1GALT1 knockout creates a powerful tool to dissect the role of O-glycosylation in hepatic tumor cell behavior and endothelial-like functions. The accumulation of Tn antigen on surface receptors may alter cell adhesion, migration, and invasion, providing insights into metastatic mechanisms. Given SK-HEP-1’s dual epithelial-endothelial features, this model can be used to explore how truncated O-glycans affect angiogenic signaling, immune evasion, and tumor microenvironment interactions. The polyclonal nature of the knockout population ensures that downstream functional studies capture a spectrum of editing events, reinforcing the generalizability of observed phenotypes across a genetically diverse cell pool.
This polyclonal C1GALT1 knockout cell product is well-suited for detailed glycobiology investigations, including lectin blotting and flow cytometry to characterize Tn and T antigen expression. Researchers can employ cell adhesion, migration, and invasion assays to assess the impact of O-glycan truncation on cellular motility and metastatic potential. Additionally, T-synthase activity assays can confirm loss of C1GALT1 function, while immunofluorescence and western blotting enable analysis of downstream glycoprotein targets. Studies on Notch signaling and immune cell interactions are also facilitated by this model. For further technical information or to inquire about custom cell engineering services, please contact Ascent Research.
